MEMonika Engelhardt

Monika Engelhardt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monika Engelhardt has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comprehensive assessment (CA) of organ function and comorbidities in a large consecutive multiple myeloma patient cohort.

    by D. De Pasquale, M. Kleber, G. Ihorst, M. Terhorst, B. Deschler, M. M. Engelhardt

    E18523 Background: MM is a frequent hematological cancer, typically affecting elderly patients. Individualized disease management has substantially improved MM-outcome. The prognostic importance of comorbidities is increasingly recognized. We aimed to define which comorbidities substantially affect PFS and OS and which of various comorbidity scores is most valuable. Methods: We retrospectively assessed 466 consecutive MM patients treated in our department between 2003-2009. Comorbidity was scored via Kaplan Feinstein (KF), HCT-CI and KLeber-score (Karnofsky-index, lung function and eGFR). Treatment was given according to institutional/international guidelines with SCT in transplant-eligible patients, and standard-therapy plus novel agents in elderly patients. Results: Patients showed a median age of 62 years (range; 27-90). Increasing CKD stages (1->5) were associated with increased age (58->63years), increased D&S and ISS-stages (median ISS 2->3), reduced KI (90->70%), impaired organ- function, anemia (11.8->9.6g/dl) and hypoalbuminemia (3.8->3.2g/dl), whereas ß2-MG (3.2->23.6mg/dl), LDH (217->292U/l), HCT-CI (1->5) and KLeber-indices (1->2) increased. Univariate analysis determined moderate or severe pulmonary disease, RF, decreased KI, age >59years, secondary neoplasms (SN), adverse cytogenetics, ß2-MG, albumin, hemoglobin and LDH to significantly diminish PFS and OS. The KF-, HCT-CI- and KLeber-score led to significantly different OS rates of not reached (nr) vs. 57 months (ms; KF with 2 vs. 3 risk factors [rfs]), 135 vs. 53ms (HCT-CI with 1 rfs) and nr vs. 86 and 39ms (KLeber with 0, 1 vs. 2 or 3 rfs; log-rank test), respectively. Conclusions: Comorbidities in MM are frequent. Important prognostic determinants for diminished PFS and OS are pulmonary disease, impaired RF, decreased KI, age >59years, SN, adverse cytogenetics, ß2-MG, albumin, hemoglobin and LDH. With only 1-point-score difference, the KF, HCT-CI and KLeber-indices induced significant OS changes. Our results highlight the debate on CA which seems vastly useful to implement into future analyses and clinical trials. Our defined risk factors and comorbidity scores should prove decidedly valuable. No significant financial relationships to disclose.


  • Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin D1 overexpression as a potential prognostic marker for response to treatment

    by T. B. Ngo, J. Felthaus, G. Ihorst, M. Engelhardt, R. Wäsch

    8614 Background: Cyclin D1 (CCND1), 2 (CCND2) and 3 (CCND3) are overexpressed in almost all MM and their deregulation has prognostic value. As cyclins are substrates of the proteasome, proteasome inhibition by bortezomib may stabilize the cell cycle and facilitate the induction of apoptosis, as it has been recently shown for breast cancer (Ishii et al, J Nat Canc Inst 2006). Methods: In a clinical approach, our objective was to define the expression levels of D-type cyclins in MM pts treated with bortezomib at our medical center between 1/2003 and 3/2006, aiming to define cyclins D as prognostic markers for monitoring treatment efficacy. We analyzed CCND1, CCND2 and CCND3 by real-time PCR in bone marrow specimens of 20 pts and correlated the expression with clinical features and other prognostic markers such as BM infiltration (BMI), ß2-microglobulin (ß2-MG) levels, 13q14 status and light chain-secretion. Results: The median number of bortezomib cycles in all pts was three and the best response to therapy was CR in one, PR in 11, SD in five and PD in 3/20. All pts who responded to bortezomib showed overexpression (OE) of CCND1. Pts not responding to bortezomib had very low or negative CCND1 cDNA levels. By 3/2007, 50% of all pts in CR, PR or SD had eventually relapsed. Of those pts, three relapsed, despite CCND1 OE prior to therapy. Six pts (66%) with CCND1 OE remained in response. Four pts displaying very high cyclin D1 expression levels were in either PR or SD, even after a follow-up of up to six years. Pts with CCND2 and CCND3 OE responded to bortezomib, but showed a relatively higher relapse rate (50% and 75% respectively). The amplification of the cyclin D genes was not found to correlate with BMI, ß2-MG, light chain secretion or del 13q14. The risk for progression after bortezomib treatment was significantly decreased in pts with cyclin D1 OE (HR 0.102, 95%CI 0.021–0.498, p=0.0048). Consequently, the progression free survival was significantly prolonged with cyclin D1 OE compared to those pts with low or negative cyclin D1 cDNA levels (p=0.0011). Conclusions: Our findings raise the possibility that CCND1 is a specific marker for predicting a lasting response after bortezomib treatment in MM, warranting a prospective study with a larger patient cohort. No significant financial relationships to disclose.

  • Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses

    by P. S. Haas, U. Denz, G. Ihorst, M. Engelhardt

    In this single-center analysis, we assessed whether lower thalidomide doses are feasible and result in favourable treatment response in multiple myeloma (MM) patients. Between May 2001 and October 2006, 38 consecutive MM patients received thalidomide. Their median age was 62.4 yr, all had stage II/III MM and 31.6% had deletion 13q14 (del13q14). Prior to thalidomide, patients had received a median of two treatment lines. The median thalidomide dose was 100 mg/d (range 50-800) and the median treatment duration was 34 wk. The median cumulative thalidomide dose was 24 g. Sixteen patients received thalidomide as a single agent and 22 in combination (+dexamethasone n = 18; others n = 4). The median time-to-treatment failure (TTF) after thalidomide initiation was 30.4 wk. Analysis of prognostic factors showed a significantly prolonged TTF without del13q14 (38.1 vs. 8.9 wk with del13q14; P = 0.006). Our analysis of TTF between thalidomide given alone vs. in combinations showed a better TTF for the combination (23.6 vs. 30.6 wk), albeit not reaching significance (P = 0.20). Other parameters, such as age, stage, and prior SCT showed no difference in TTF. Peripheral polyneuropathy (PNP) frequencies were increased with longer (>28 wk) and increased cumulative thalidomide doses (>40 g), which emphasizes (a) the need to carefully escalate thalidomide from 50 to 200 mg/d, thereby reducing side effects and increasing patient compliance, and (b) that PNP occurs more frequently with longer and higher thalidomide doses. The strategy to lower thalidomide doses seems a feasible and attractive approach in MM patients, this being currently tested in prospective randomized trials.


  • Proteasominhibition als neues Therapiekonzept

    by R. Wäsch, U. Denz, M. Engelhardt

    Das Ubiquitin-Proteasom-System ist ein zentraler Mechanismus zum Abbau nicht mehr benötigter oder fehlerhafter zellulärer Proteine. Nach Markierung der Zielproteine mit Ketten aus dem Polypeptid Ubiquitin können diese Proteine vom sog. 26S-Proteasom zerstört werden. Die Hemmung dieses Systems durch kleine Moleküle hat vielfältige Auswirkungen auf die Zellproliferation. Präklinische und klinische Studien mit Proteasominhibitoren haben die Sicherheit und Wirksamkeit dieser neuartigen Therapieoption für maligne Erkrankungen eindrucksvoll belegt. Die erste zugelassene Substanz Bortezomib scheint die größte Wirkung beim Multiplen Myelom zu entfalten, hat sich aber auch bei anderen Non-Hodgkin-Lymphomen als effektiv erwiesen. Hervorzuheben ist die Fähigkeit von Proteasominhibitoren, in Kombination mit Chemotherapeutika eine Chemoresistenz zu durchbrechen. Durch Integration von Bortezomib in Induktions-, Erhaltungs- oder Rezidivtherapien scheinen bestehende Behandlungskonzepte entscheidend weiterentwickelt werden zu können. Ziel ist dabei, ein verbessertes Behandlungsergebnis mit geringen oder tolerablen Nebenwirkungen zu erreichen. The ubiquitin-proteasome-pathway is a central mechanism in degrading regulatory or damaged proteins in living cells. Target proteins tagged with polyubiquitin-chains are recognized and rapidly degraded by the 26 S proteasome. The inhibition of this pathway by small molecule inhibitors interferes with cell proliferation in multiple ways. Pre-clinical and clinical studies with proteasome inhibitors impressively demonstrated the safety and efficiency of this new therapeutic option for malignant diseases. The first approved substance bortezomib seems to be most effective in multiple myeloma and some other non-Hodgkin lymphomas. The ability of proteasome inhibitors in combination with chemotherapy to overcome chemoresistance can also be effective in other malignancies, such as solid tumors. The integration of bortezomib in induction, consolidation and salvage therapies seems to significantly improve current treatment options. The ultimate goal is to achieve optimal tumor regression with minimal or tolerable side effects.


  • Innovative Antikörper-Therapien bei malignen Lymphomen

    by A. M. S. Müller, J. Rawluk, V. Thierry, I. Brink, M. Engelhardt

    Non-Hodgkin-Lymphome (NHL) sind eine in ihrer Inzidenz stetig zunehmende Gruppe maligner lymphatischer Neoplasien, an denen insbesondere Ältere erkranken. Aufgrund dieser Altersverteilung ist es unerlässlich, neue und gut verträgliche Behandlungsoptionen - neben „konventionellen“ Therapien, wie der Standardchemo- oder Hochdosischemotherapie mit Stammzelltransplantation - zu prüfen. Als eine dieser neuen, zielgerichteten Therapien haben sich monoklonale Antikörper, wie der anti-CD20-Antikörper Rituximab, etabliert. Andere, wie der anti-CD52-Antikörper Alemtuzumab, stehen für die Behandlung der chronisch lymphatischen Leukämie (CLL) sowie von T-Zell-Lymphomen zur Verfügung und werden in klinischen Studien geprüft. Als Weiterentwicklung zielgerichteter Therapeutika werden kombinierte Radioimmuntherapien für den klinischen Einsatz verwendet. Erste Erfahrungen bei fortgeschrittenen, indolenten Lymphomen sind vielversprechend. Der Einsatz bei aggressiven Lymphomen und in der Primärtherapie wird weiter in Studien geprüft. Dieser Beitrag soll einen Überblick über den klinischen Einsatz und die bisherigen Studienergebnisse innovativer Immuntherapien geben, wobei insbesondere auf die Indikationsgebiete und praktische Anwendung im klinischen Alltag eingegangen wird. Non-HodgkinŽs lymphoma (NHL) includes a group of malignant lymphoproliferative disorders, that particularly occur in the elderly and have an continuously increasing incidence. Because of the age distribution new treatment options with low toxicity and minor side effects - apart from „conventional“ therapies like standard or high dose chemotherapy - are needed. Within these novel therapeutic modalities the use of the monoclonal antibody rituximab has been widely established. Other monoclonal antibodies, such as the anti-CD52-antibody alemtuzumab, are available for the treatment of chronic lymphatic leukemia (CLL) and T-cell-lymphomas and are being tested in clinical trials. Furthermore the option of combining targeted therapies, in which antibodies are used with radiotherapy, has led to the development of radio-immunotherapies that are now becoming available for clinical use. Current results in the treatment of advanced indolent lymphomas are promising, and their use in high-grade lymphoma and as first-line therapy is under investigation. This article summarizes the application of these novel immunotherapies and reviews the results of recent clinical trials, with particular emphasis on indications and practical aspects in everyday clinical life.


  • Occurrence of multiple myeloma 13 years after Hodgkin’s disease: chance or consequence?

    by Eva-Susanne Strobel, Kris Bauchmüller, Annette Schmitt-Gräff, Monika Engelhardt